Search Results - "Verslype, C"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study by Kelley, R.K., Verslype, C., Cohn, A.L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.

    Published in Annals of oncology (01-03-2017)
    “…Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular…”
    Get full text
    Journal Article
  6. 6

    Robotic versus laparoscopic repeat hepatectomy: A comparative single-center study of perioperative outcomes by Vancoillie, S., Willems, E., De Meyere, C., Parmentier, I., Verslype, C., D'Hondt, Mathieu

    Published in European journal of surgical oncology (01-01-2025)
    “…A repeat liver resection is considered a technically challenging procedure and therefor an open approach is frequently preferred. With the introduction of…”
    Get full text
    Journal Article
  7. 7

    Molecular classification of hepatocellular carcinoma anno 2011 by van Malenstein, H, van Pelt, J, Verslype, C

    Published in European journal of cancer (1990) (01-08-2011)
    “…Abstract Hepatocellular carcinoma has an increasing incidence and high mortality. Treatment options are limited if the disease is not diagnosed in its early…”
    Get full text
    Journal Article
  8. 8

    The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin by Durnez, A, Verslype, C, Nevens, F, Fevery, J, Aerts, R, Pirenne, J, Lesaffre, E, Libbrecht, L, Desmet, V, Roskams, T

    Published in Histopathology (01-08-2006)
    “…Aims:  Cytokeratin (CK) 7 and CK19 expression, present in hepatic progenitor cells (HPCs) and in cholangiocytes but not in normal hepatocytes, has been…”
    Get full text
    Journal Article
  9. 9

    The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma by Govaere, O, Petz, M, Wouters, J, Vandewynckel, Y-P, Scott, E J, Topal, B, Nevens, F, Verslype, C, Anstee, Q M, Van Vlierberghe, H, Mikulits, W, Roskams, T

    Published in Oncogene (23-11-2017)
    “…Human hepatocellular carcinomas (HCCs) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked with a poor prognosis and…”
    Get full text
    Journal Article
  10. 10

    Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study by Katoonizadeh, Aezam, Laleman, Wim, Verslype, Chris, Wilmer, Alexander, Maleux, Geert, Roskams, Tania, Nevens, Frederik

    Published in Gut (01-11-2010)
    “…'Acute-on-chronic liver failure' (ACLF) is characterised in a more advanced stage by liver failure associated with multiple other end-organ failure. The global…”
    Get more information
    Journal Article
  11. 11

    Sorafenib: from literature to clinical practice by Di Marco, V, De Vita, F, Koskinas, J, Semela, D, Toniutto, P, Verslype, C

    Published in Annals of oncology (01-04-2013)
    “…Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class)…”
    Get full text
    Journal Article
  12. 12

    Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer by VAN CUTSEM, E, VAN DE VELDE, H, SAFRAN, H, HUMBLET, Y, PEREZ RUIXO, J, MA, Y, VON HOFF, D, KARASEK, P, OETTLE, H, VERVENNE, W. L, SZAWLOWSKI, A, SCHOFFSKI, P, POST, S, VERSLYPE, C, NEUMANN, H

    Published in Journal of clinical oncology (15-04-2004)
    “…To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development,…”
    Get full text
    Journal Article
  13. 13

    Review article: blood platelet number and function in chronic liver disease and cirrhosis by WITTERS, P., FRESON, K., VERSLYPE, C., PEERLINCK, K., HOYLAERTS, M., NEVENS, F., VAN GEET, C., CASSIMAN, D.

    Published in Alimentary pharmacology & therapeutics (01-06-2008)
    “…Summary Background  The liver plays a central role in coagulation and fibrinolysis but is also closely intertwined with the function and number of blood…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Systematic review: the pathophysiology and management of polycystic liver disease by Temmerman, F., Missiaen, L., Bammens, B., Laleman, W., Cassiman, D., Verslype, C., van Pelt, J., Nevens, F.

    Published in Alimentary pharmacology & therapeutics (01-10-2011)
    “…Aliment Pharmacol Ther 2011; 34: 702–713 Summary Background  Polycystic liver diseases (PCLD) represent a group of genetic disorders in which cysts occur…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Transition from laparoscopic to robotic liver surgery: clinical outcomes, learning curve effect, and cost-effectiveness by D’Hondt, M., Devooght, A., Willems, E., Wicherts, D., De Meyere, C., Parmentier, I., Provoost, A., Pottel, H., Verslype, C.

    Published in Journal of robotic surgery (01-02-2023)
    “…The reproducibility of the implementation of robotic liver surgery (RLS) is still debated. The aim of the present study is to evaluate short-term outcomes and…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology by Borbath, I., Ceratti, A., Verslype, C., Demols, A., Delaunoit, T., Laurent, S., Deleporte, A., Vergauwe, P., Van Maanen, A., Sempoux, C., Van Cutsem, E., Van Laethem, J.L.

    Published in Annals of oncology (01-11-2013)
    “…Cholangiocarcinomas are uncommon tumours with a poor prognosis, that frequently present epidermal growth factor receptor overexpression. In a multi-centre…”
    Get full text
    Journal Article